First clinical experience with fractionated intracavitary radioimmunotherapy using [¹⁷⁷Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study.

ABSTRACT:

Background

Following resection and standard adjuvant radio- and chemotherapy, approved maintenance therapies for glioblastoma are lacking. Intracavitary radioimmunotherapy (iRIT) with ¹⁷⁷Lu-labeled 6A10-Fab fragments targeting tumor-associated carbonic anhydrase XII and injected into the resection cavity offers a novel and promising strategy for improved tumor control.

Methods

Three glioblastoma patients underwent tumor resection followed by standard radio- and chemotherapy. These patients with stable disease following completion of standard therapy underwent iRIT on compassionate grounds. After surgical implantation of a subcutaneous injection reservoir with a catheter into the resection cavity, a leakage test with [^99mTc]Tc-DTPA was performed to rule

SUBMITTER: Roll W 

PROVIDER: S-EPMC10477153 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature